오리엔트바이오
1,476KRWMarket close of 10/20 (Tue)
Down -1.99%-30KRWMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)1,439KRWDown -2.51%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 1,504
- High
- 1,542
- Low
- 1,406
- Day range
- Day range low 1,406 high 1,542, open 1,504, close 1,476, previous close 1,506
- Volume
- 18×10K shares
- 257.74 million KRW 2.42× the 20-session average
Market close of 10/20 (Tue)
Usual range
Nothing unusual in the 2 checked items
Free · no sign-inSource from 2021-05-17
Points to check
- Daily movenot verifiedOnly 16 daily bars to compare, so not verified
- Trading valuenot verifiedNot enough 20-session trading value data, so not verified
- Recent filingsnot verifiedOutside filing data coverage, so not verified
The other 3
- Foreign & institutionalnot verified
- EarningsOperating income, 4 quarters
- Data date10/20 (Tue)Market close
See the full check report
Quarterly results · Q4 2021
- Revenue6.8B KRW
- vs. year ago
- —
- vs. prior quarter
- -60.3%
- Operating income571.28 million KRW
- vs. year ago
- —
- vs. prior quarter
- -43.6%
- Operating margin8.4%
- vs. year ago
- —
- vs. prior quarter
- +2.5 pp
This quarter is derived: annual results minus Q1–Q3.
Quarterly operating income trend
As of the latest official close · 2026-10-20Valuation filing date · 2022-02-14Same sector · 제약
Down -1.68%· 29 of 168 stocks up, preferred shares excluded · trading value 827.8B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 셀트리온 | Close over the last 20 sessions +11.4% | Down -0.40% | 139.2B KRW |
| 삼성바이오로직스 | Close over the last 20 sessions -1.3% | Down -2.52% | 129.9B KRW |
| 삼익제약 | Close over the last 20 sessions -20.4% | Up +2.77% | 76.0B KRW |
| 녹십자엠에스 | Close over the last 20 sessions +30.5% | Up +6.67% | 55.6B KRW |
| 유한양행 | Close over the last 20 sessions +11.5% | Down -1.37% | 41.6B KRW |
Schedule
- Next data 10/22 (Thu) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 81% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.